Sign In
15 Feb 2022 07:00
15 February 2022
Graft Polymer (UK) Plc
("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")
Change of Year End
Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development of polymer modification, biological supplements and drug delivery systems, announces that the year-end for the Company has changed from 31 May to 31 December.
Accordingly, the financial period which commenced on 1 June 2021 ended on 31 December 2021 and the Company will report FY results in accordance with the current listing requirements being on or before 30 June 2022.
----- END -----
For more information, please visit https://www.graftpolymer.com or contact:
Graft Polymer (UK) Plc | via Tavistock |
Roby Zomer, Chairman | |
Yifat Steuer, CFO | |
Turner Pope Investments (Broker) | +44 20 3657 0050 |
James Pope | |
Andy Thacker | |
Tavistock (Public Relations) | +44 207 920 3150 |
Heather Armstrong | graftpolymer@tavistock.co.uk |
Katie Hopkins |
About Graft Polymer
Graft Polymer is a UK incorporated holding company with an innovative research and manufacturing facility, based in Slovenia. The core business of the Group comprises polymer modification and drug delivery systems developments. Established in 2017, the Group has already introduced more than 50 products to the market.
The Group has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.
In particular, the Group's techniques allow the combination of otherwise incompatible polymers, facilitating the creation of polymer composites engineered at a molecular level, that combine the attractive properties of different input materials. This enables customers to receive a synergism of properties in polymer composites.
The solutions and products offered by the Group are designed to improve performance, reduce raw materials consumption, and enhance the physical characteristic values of finished products or improve or modify their chemical interaction. In the past several years, there has been increased emphasis by the industry as a whole on applications of grafted polymers, which are produced by monomers being covalently bonded and polymerised as side chains onto the main polymer chain (the backbone).
In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic. The GraftBio division is in the process of obtaining the HACCP certification for its production facility. The Group has developed a set of drug delivery platforms that enable it to licence its DDS platform (IP) to MGC Pharmaceuticals Limited ("MGC"; LSE: MXC) in relation to MGC's CimetrA™ and CannEpil-IL™ products. The Group expects to receive royalty payments resulting from the sale by MGC of CimetrA™ and CannEpil-IL™ products.
Follow the stocks
